30 Years Later: A New Hope for Pancreatic Cancer! 🎗️ #FDA has approved @Novocure 's #Optune Pax, the first wearable electric field therapy for locally advanced pancreatic cancer. This non-invasive, drug-free device uses TTFields technology to physically disrupt cancer cell

TTFields (+chemo) now @US_FDA ✅ for locally advanced pancreatic ductal adenocarcinoma based off #PANOVA3: - mOS 16.2 vs. 14.2mos (HR: 0.82) - AEs: 76% device related skin side effects - Is this going to be rapidly adopted in practice? #gism #OncTwitter #MedTwitter #pancsm

The FDA has approved TTFields in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. Phase 3 PANOVA-3: n≈570 Gemcitabine + nab-paclitaxel ± TTFields Median OS: 16.2 vs 14.2 months HR ≈0.82 No increase in systemic toxicity. Most common AE: localized

Novocure announced that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma (GBM). 💙Read more: https://t.co/jfec7wVrXn #TTFields #Novocure #BCCancer

🚨 The FDA has approved Optune Pax (TTFields) for the treatment of patients with locally advanced pancreatic cancer. TTFields in PANOVA-3: ⭐ mOS = 16.2 mos (HR, 0.82) ⭐ mPain-free survival = 15.2 mos (HR, 0.74) ⭐ Grade ≥3 TRAEs = 88.7% Read here ➡️ https://t.co/uKPUE3TnVk

A new modality has entered the pancreatic cancer paradigm!💊 Following the @US_FDA approval of Optune Pax, Vincent Picozzi, MD, @VMhealth, discusses how TTFields may help expand multimodal treatment strategies and open the door for future combination approaches. Watch the

🧠⚡ PANOVA-3: TTFields in LA-PAC 🧪 TTFields + Gem/NabPac vs chemo alone 👥 n=571 | 📍 Phase 3 | 🎯 OS primary ✅ OS: 16.2 vs 14.2 mo 📉 HR 0.82 [0.68–0.99], p=0.039 🩻 1-yr OS: 68% vs 60% ❌ No PFS or local PFS benefit 📍 Distant PFS only in post-hoc 😣 81% device-related AEs

🎯 Top Sessions to Watch at #ESMOGI25 🔥 From practice-changing data to paradigm debates 👇 🔵 Late Breakers: 1️⃣ MATTERHORN (LBA4) – Durva+FLOT: EFS & PROs in G/GEJ 2️⃣ PANOVA-3 (LBA3) – TTFields: QoL & pain in LAPC 3️⃣ TALENTACE (LBA2) – Atezo/Bev+TACE in HCC: Phase 3 results 🚀

Tumor Treating Fields (TTFields) have been approved by the FDA for pancreatic cancer👇

Tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for LA-PDAC #ASCO25 🔎PANOVA-3 phs 3 👉mPFS 10.6 vs9.3 mo 👉mDFS 13.9 vs 11.5 👉mOS 16.2 vs 14.2 mo 👉better Qol & pain free survival, but skin tox 🧐Positive, but interesting to see whether & how it will

🚨 PANOVA-3 Phase III Breakthrough 🚨 In unresectable locally advanced pancreatic cancer (LA-PAC), adding Tumor Treating Fields (TTFields) to gemcitabine + nab-paclitaxel offers meaningful clinical gains 📈 🎯 Key Results: 🧠 OS ↑: 16.2 vs 14.2 mo (HR 0.82, P=.039) 😌 Pain-free

PANOVA-03 LAPC GnP vs GnP + TTFields #ASCO25 @ASCO @OncoAlert ➡️571 patients randomised ➡️mOS 16.2 mths vs 14.2mths ➡️pain free survival longer ➡️mainly skin reactions for TTFields

Dr. @NiuSanford discusses the PANOVA-3 trial, which found an improvement in OS for pts w unresectable, locally adv pancreatic adenocarcinoma treated in the first line w TTFields concomitant w gemcitabine & nab-paclitaxel. Learn more: https://t.co/rzWEBjV6rF #ASCO25

$NVCR Novocure’un Beyin Kanseri Tedavisi Artık İspanya’da Ücretsiz Sunuluyor! Novocure, İspanya Sağlık Bakanlığı'nın yeni teşhis edilen glioblastomlu (En ölümcül ve en agresif primer beyin tümörü) yetişkin hastalar için Tümör Tedavi Alanları (TTFields) tedavisini İspanya Ulusal

Yesterday, @US_FDA approved Optune Pax, a medical device that delivers alternating electrical fields called tumor treating fields (TTFields) to the abdomen, for the treatment of adult patients with locally advanced pancreatic cancer:

The FDA approved a tumor treating fields (TTFields) device for locally advanced pancreatic cancer, the first therapy approved in this setting in nearly 30 years. https://t.co/O8QhzYALp0

🧲⚡ METIS Trial: TTFields after SRS in NSCLC brain mets — hype or hope? ℹ️ Tumor Treating Fields (TTFields) = Low-intensity alternating electric fields delivered via scalp arrays, disrupting tumor cell division and delaying progression without cognitive harm. 👥 Population 🫁

ASCOのレビューをしていて、驚いたのですが、腫瘍電場療法（TTFields)というのがあって、���臓がんのOSを有意に延長していました。 https://t.co/2NfEpzborh

🚨 PANOVA-3 in #ASCO25: TTFields + GnP vs GnP in LA-PDAC Is this the spark that makes TTFields matter in pancreas? 🤔 🎯mOS: 16.2 vs 14.2 mo (HR 0.82, p=0.039) 🎯Pain-free survival: 15.2 vs 9.1 mo (HR 0.74, p=0.027) Electric thinking meets clinical grounding

PANOVA-3 phase III results for locally advanced #PancreaticCancer: Tumor Treating Fields (TTFields) = Gem + nab-pac: ✅ OS: 16.2 vs. 14.2 m (HR 0.82) ✅ Distant PFS 13.9 vs 11.5 m No added systemic toxicity. . #ASCO #Oncology #GIcancer #CancerResearch #TTFields #PancreaticCancer